Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 674

1.

Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.

Daniels K, McKee M.

J R Army Med Corps. 1995 Oct;141(3):142-50. Erratum in: J R Army Med Corps 1996 Feb;142(1):49.

PMID:
8568748
2.

Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1.

3.

Cost-effectiveness of screening for colorectal cancer in the general population.

Frazier AL, Colditz GA, Fuchs CS, Kuntz KM.

JAMA. 2000 Oct 18;284(15):1954-61.

PMID:
11035892
4.

Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM.

Int J Cancer. 2015 Jun 15;136(12):2864-74. doi: 10.1002/ijc.29343. Epub 2014 Dec 3.

5.

Options for screening for colorectal cancer.

Atkin W.

Scand J Gastroenterol Suppl. 2003;(237):13-6. Review.

PMID:
12797674
6.

Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.

Tsoi KK, Ng SS, Leung MC, Sung JJ.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):353-63. doi: 10.1111/j.1365-2036.2008.03726.x.

7.

Cost-effectiveness of colonoscopy in screening for colorectal cancer.

Sonnenberg A, Delcò F, Inadomi JM.

Ann Intern Med. 2000 Oct 17;133(8):573-84.

PMID:
11033584
8.

Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer [Internet].

Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Dec 20.

9.

Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.

van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E.

Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25.

PMID:
18482589
10.

A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population [Internet].

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9.

11.

Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.

Parente F, Boemo C, Ardizzoia A, Costa M, Carzaniga P, Ilardo A, Moretti R, Cremaschini M, Parente EM, Pirola ME.

Endoscopy. 2013;45(1):27-34. doi: 10.1055/s-0032-1325800. Epub 2012 Dec 19.

PMID:
23254404
12.

Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y.

Aliment Pharmacol Ther. 2009 Feb 15;29(4):450-7. doi: 10.1111/j.1365-2036.2008.03898.x. Epub 2008 Nov 17.

13.

The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.

Sweet A, Lee D, Gairy K, Phiri D, Reason T, Lock K.

Appl Health Econ Health Policy. 2011;9(1):51-64. doi: 10.2165/11588110-000000000-00000.

PMID:
21174482
14.

Screening of colorectal cancer.

Winawer SJ.

Surg Oncol Clin N Am. 2005 Oct;14(4):699-722. Review.

PMID:
16226687
15.

Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.

Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M.

J Med Screen. 2002;9(3):99-103.

PMID:
12370319
16.

Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y.

Aliment Pharmacol Ther. 2009 Apr 15;29(8):906-17. doi: 10.1111/j.1365-2036.2009.03946.x.

17.

Inappropriate use of the faecal occult blood test outside of the National Health Service colorectal cancer screening programme.

Peacock O, Watts ES, Hanna N, Kerr K, Goddard AF, Lund JN.

Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1270-5.

PMID:
22872076
18.

Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.

Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupé VMH.

Ann Intern Med. 2017 Oct 17;167(8):544-554. doi: 10.7326/M16-2891. Epub 2017 Oct 3.

PMID:
28973514
19.

Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.

Lee D, Muston D, Sweet A, Cunningham C, Slater A, Lock K.

Appl Health Econ Health Policy. 2010;8(3):141-54. doi: 10.2165/11535650-000000000-00000.

PMID:
20369905
20.

Supplemental Content

Support Center